Research ExplorerPublicationsMulticentre, phase II trial on the safety and efficacy of to...

Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus.

Standard

Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. / Hengge, U R; Krause, W; Hofmann, H; Stadler, R; Gross, G; Meurer, M; Brinkmeier, T; Frosch, P; Moll, Ingrid; Fritsch, P; Müller, K; Meykadeh, N; Marini, A; Ruzicka, T; Gollnick, H.

In: BRIT J DERMATOL, Vol. 155, No. 5, 5, 2006, p. 1021-1028.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hengge, UR, Krause, W, Hofmann, H, Stadler, R, Gross, G, Meurer, M, Brinkmeier, T, Frosch, P, Moll, I, Fritsch, P, Müller, K, Meykadeh, N, Marini, A, Ruzicka, T & Gollnick, H 2006, 'Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus.', BRIT J DERMATOL, vol. 155, no. 5, 5, pp. 1021-1028. <http://www.ncbi.nlm.nih.gov/pubmed/17034535?dopt=Citation>

APA

Hengge, U. R., Krause, W., Hofmann, H., Stadler, R., Gross, G., Meurer, M., Brinkmeier, T., Frosch, P., Moll, I., Fritsch, P., Müller, K., Meykadeh, N., Marini, A., Ruzicka, T., & Gollnick, H. (2006). Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. BRIT J DERMATOL, 155(5), 1021-1028. [5]. http://www.ncbi.nlm.nih.gov/pubmed/17034535?dopt=Citation

Vancouver

Hengge UR, Krause W, Hofmann H, Stadler R, Gross G, Meurer M et al. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. BRIT J DERMATOL. 2006;155(5):1021-1028. 5.

Bibtex

@article{17ca0263b6064e4a80d0be713a9019df,
title = "Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus.",
abstract = "BACKGROUND: Lichen sclerosus is a chronic inflammatory autoimmune disease causing significant sclerosis, atrophy and pruritus. Treatment remains unsatisfactory, with potent corticosteroids being the most effective therapy. OBJECTIVES: To conduct a multicentre, phase II trial to assess the safety and efficacy of tacrolimus ointment 0.1% for the treatment of lichen sclerosus with a follow-up period of 18 months at 10 university and teaching hospitals in Germany and Austria. METHODS: Eighty-four patients (49 women, 32 men and three girls) aged between 5 and 85 years with long-standing, active lichen sclerosus (79 with anogenital and five with extragenital localization) were treated with topical tacrolimus ointment 0.1% twice daily for 16 weeks. Computerized analysis of the lesional area was performed. The primary endpoint was clearance of active lichen sclerosus. Secondary endpoints were time to optimal response, reduction of sclerosis and duration of remission. RESULTS: The primary endpoint (clearance of active lichen sclerosus) was reached by 43% of patients at 24 weeks of treatment. Partial resolution was reached in 34% of patients. Maximal effects occurred between week 10 and 24 of therapy. Treatment led to a significant reduction of the total lesional area (P <0.01) and to a significant decline in the total symptom score (P <0.005). Symptoms (e.g. itching) and findings (erythema, erosions and induration) showed significant improvement. No serious adverse events were observed. There were three (9%) recurrences during the follow-up period. CONCLUSIONS: Topical tacrolimus ointment 0.1% was safe and effective for the treatment of long-standing active lichen sclerosus.",
author = "Hengge, {U R} and W Krause and H Hofmann and R Stadler and G Gross and M Meurer and T Brinkmeier and P Frosch and Ingrid Moll and P Fritsch and K M{\"u}ller and N Meykadeh and A Marini and T Ruzicka and H Gollnick",
year = "2006",
language = "Deutsch",
volume = "155",
pages = "1021--1028",
journal = "BRIT J DERMATOL",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus.

AU - Hengge, U R

AU - Krause, W

AU - Hofmann, H

AU - Stadler, R

AU - Gross, G

AU - Meurer, M

AU - Brinkmeier, T

AU - Frosch, P

AU - Moll, Ingrid

AU - Fritsch, P

AU - Müller, K

AU - Meykadeh, N

AU - Marini, A

AU - Ruzicka, T

AU - Gollnick, H

PY - 2006

Y1 - 2006

N2 - BACKGROUND: Lichen sclerosus is a chronic inflammatory autoimmune disease causing significant sclerosis, atrophy and pruritus. Treatment remains unsatisfactory, with potent corticosteroids being the most effective therapy. OBJECTIVES: To conduct a multicentre, phase II trial to assess the safety and efficacy of tacrolimus ointment 0.1% for the treatment of lichen sclerosus with a follow-up period of 18 months at 10 university and teaching hospitals in Germany and Austria. METHODS: Eighty-four patients (49 women, 32 men and three girls) aged between 5 and 85 years with long-standing, active lichen sclerosus (79 with anogenital and five with extragenital localization) were treated with topical tacrolimus ointment 0.1% twice daily for 16 weeks. Computerized analysis of the lesional area was performed. The primary endpoint was clearance of active lichen sclerosus. Secondary endpoints were time to optimal response, reduction of sclerosis and duration of remission. RESULTS: The primary endpoint (clearance of active lichen sclerosus) was reached by 43% of patients at 24 weeks of treatment. Partial resolution was reached in 34% of patients. Maximal effects occurred between week 10 and 24 of therapy. Treatment led to a significant reduction of the total lesional area (P <0.01) and to a significant decline in the total symptom score (P <0.005). Symptoms (e.g. itching) and findings (erythema, erosions and induration) showed significant improvement. No serious adverse events were observed. There were three (9%) recurrences during the follow-up period. CONCLUSIONS: Topical tacrolimus ointment 0.1% was safe and effective for the treatment of long-standing active lichen sclerosus.

AB - BACKGROUND: Lichen sclerosus is a chronic inflammatory autoimmune disease causing significant sclerosis, atrophy and pruritus. Treatment remains unsatisfactory, with potent corticosteroids being the most effective therapy. OBJECTIVES: To conduct a multicentre, phase II trial to assess the safety and efficacy of tacrolimus ointment 0.1% for the treatment of lichen sclerosus with a follow-up period of 18 months at 10 university and teaching hospitals in Germany and Austria. METHODS: Eighty-four patients (49 women, 32 men and three girls) aged between 5 and 85 years with long-standing, active lichen sclerosus (79 with anogenital and five with extragenital localization) were treated with topical tacrolimus ointment 0.1% twice daily for 16 weeks. Computerized analysis of the lesional area was performed. The primary endpoint was clearance of active lichen sclerosus. Secondary endpoints were time to optimal response, reduction of sclerosis and duration of remission. RESULTS: The primary endpoint (clearance of active lichen sclerosus) was reached by 43% of patients at 24 weeks of treatment. Partial resolution was reached in 34% of patients. Maximal effects occurred between week 10 and 24 of therapy. Treatment led to a significant reduction of the total lesional area (P <0.01) and to a significant decline in the total symptom score (P <0.005). Symptoms (e.g. itching) and findings (erythema, erosions and induration) showed significant improvement. No serious adverse events were observed. There were three (9%) recurrences during the follow-up period. CONCLUSIONS: Topical tacrolimus ointment 0.1% was safe and effective for the treatment of long-standing active lichen sclerosus.

M3 - SCORING: Zeitschriftenaufsatz

VL - 155

SP - 1021

EP - 1028

JO - BRIT J DERMATOL

JF - BRIT J DERMATOL

SN - 0007-0963

IS - 5

M1 - 5

ER -